Rapamycin reduces VEGF expression in retinal pigment epithelium (RPE) and inhibits RPE-induced sprouting angiogenesis in vitro

FEBS Letters

Volumn 582, Issue 20, 2008, Pages 3097-3102

  Stahl, A ^a   Paschek, L ^a   Martin, G ^a   Gross, N J ^a   Feltgen, N ^a   Hansen, L L ^a   Agostini, H T ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Angiogenesis; CNV; Endothelial; Rapamycin; RPE; Spheroid

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; BEVACIZUMAB; RANIBIZUMAB; RAPAMYCIN; VASCULOTROPIN;

ANGIOGENESIS; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IN VITRO STUDY; PIGMENT EPITHELIUM; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPROUTING;

ANGIOGENESIS INHIBITORS; APOPTOSIS; CELLS, CULTURED; CHOROIDAL NEOVASCULARIZATION; COCULTURE TECHNIQUES; HUMANS; PIGMENT EPITHELIUM OF EYE; SIROLIMUS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 49649105189     PISSN: 00145793     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.febslet.2008.08.005     Document Type: Article

References (42)

1. Kliffen M., Sharma H.S., Mooy C.M., Kerkvliet S., and de Jong P.T. Increased expression of angiogenic growth factors in age-related maculopathy. Br. J. Ophthalmol. 81 (1997) 154-162
2. Brown D.M., and Regillo C.D. Anti-VEGF agents in the treatment of neovascular age-related macular degeneration: applying clinical trial results to the treatment of everyday patients. Am. J. Ophthalmol. 144 (2007) 627-637
3. D'Amico D.J., Masonson H.N., Patel M., Adamis A.P., Cunningham Jr. E.T., Guyer D.R., and Katz B. Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials. Ophthalmology 113 (2006) 992 e6-1001 e6
4. Rosenfeld P.J., Brown D.M., Heier J.S., Boyer D.S., Kaiser P.K., Chung C.Y., and Kim R.Y. Ranibizumab for neovascular age-related macular degeneration. New Engl. J. Med. 355 (2006) 1419-1431
5. Brown D.M., Kaiser P.K., Michels M., Soubrane G., Heier J.S., Kim R.Y., Sy J.P., and Schneider S. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. New Engl. J. Med. 355 (2006) 1432-1444
6. Regillo C.D., Brown D.M., Abraham P., Yue H., Ianchulev T., Schneider S., and Shams N. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am. J. Ophthalmol. 145 (2008) 239-248
7. Rosenfeld P.J., Moshfeghi A.A., and Puliafito C.A. Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. Ophthal. Surg. Lasers Imaging 36 (2005) 331-335
8. Avery R.L., Pieramici D.J., Rabena M.D., Castellarin A.A., Nasir M.A., and Giust M.J. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 113 (2006) 363 e5-372 e5
9. Spaide R.F., et al. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 26 (2006) 383-390
10. Aisenbrey S., Ziemssen F., Volker M., Gelisken F., Szurman P., Jaissle G., Grisanti S., and Bartz-Schmidt K.U. Intravitreal bevacizumab (Avastin) for occult choroidal neovascularization in age-related macular degeneration. Graefes Arch. Clin. Exp. Ophthalmol. 245 (2007) 941-948
11. Bian Z.M., Elner S.G., and Elner V.M. Regulation of VEGF mRNA expression and protein secretion by TGF-beta2 in human retinal pigment epithelial cells. Exp. Eye Res. 84 (2007) 812-822
12. Guba M., et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat. Med. 8 (2002) 128-135
13. Sausville E.A., Elsayed Y., Monga M., and Kim G. Signal transduction-directed cancer treatments. Annu. Rev. Pharmacol. Toxicol. 43 (2003) 199-231
14. Dichtl W., et al. Countervailing effects of rapamycin (sirolimus) on nuclear factor-kappa B activities in neointimal and medial smooth muscle cells. Atherosclerosis 186 (2006) 321-330
15. Shi W., Gao H., Xie L., and Wang S. Sustained intraocular rapamycin delivery effectively prevents high-risk corneal allograft rejection and neovascularization in rabbits. Invest. Ophthalmol. Vis. Sci. 47 (2006) 3339-3344
16. Kwon Y.S., and Kim J.C. Inhibition of corneal neovascularization by rapamycin. Exp. Mol. Med. 38 (2006) 173-179
17. Dejneka N.S., Kuroki A.M., Fosnot J., Tang W., Tolentino M.J., and Bennett J. Systemic rapamycin inhibits retinal and choroidal neovascularization in mice. Mol. Vis. 10 (2004) 964-972
18. Dugel, D.U., Quiroz-Mercado, H., Kleinman, D.M., Weber, D.A., Williams, G.A., Haller, J.A., and Blumenkranz, M.S. (2008). In: ARVO, Fort Lauderdale, FL, USA.
19. Blumenkranz, M.S., Dugel, P., Solley, W.A., Kleinman, D.M., Weber, D.A., Williams, G.A., Haller, J.A. (2008). In: ARVO, Fort Lauderdale, FL, USA.
20. Moreno-Paramo, D., Velez-Montoya, R., Flores-Estrada, J., Rodriguez-Reyes, A., Hernandez-Ayuso, I., Torres-Porras, E., Romo-Garcia, E., Hitos-Fajer, A., Garcia-Aguirre, G., Quiroz-Mercado, H. (2008). In: ARVO, Fort Lauderdale, FL, USA.
21. Romo-Garcia, E., Moreno-Paramo, D., Velez-Montoya, R., Flores-Estrada, J., Hitos-Fajer, A., Torres-Porras, E., Hernandez-Ayuso, I., Garcia-Aguirre, G., Rodriguez-Reyes, A., Quiroz-Mercado, H. (2008). In: ARVO, Fort Lauderdale, FL, USA.
22. Salmon, J.H., Douglas, L., Yi, N., Davis, J.L., Gilger, B.C. (2008). In: ARVO, Fort Lauderdale, FL, USA.
23. Korff T., and Augustin H.G. Integration of endothelial cells in multicellular spheroids prevents apoptosis and induces differentiation. J. Cell Biol. 143 (1998) 1341-1352
24. Schlunck G., Martin G., Agostini H.T., Camatta G., and Hansen L.L. Cultivation of retinal pigment epithelial cells from human choroidal neovascular membranes in age related macular degeneration. Exp. Eye Res. 74 (2002) 571-576
25. Korff T., and Augustin H.G. Tensional forces in fibrillar extracellular matrices control directional capillary sprouting. J. Cell Sci. 112 Pt 19 (1999) 3249-3258
26. Stahl A., Wu X., Wenger A., Klagsbrun M., and Kurschat P. Endothelial progenitor cell sprouting in spheroid cultures is resistant to inhibition by osteoblasts: a model for bone replacement grafts. FEBS Lett. 579 (2005) 5338-5342
27. Bianco R., et al. Inhibition of mTOR pathway by everolimus cooperates with EGFR inhibitors in human tumours sensitive and resistant to anti-EGFR drugs. Br. J. Cancer 98 (2008) 923-930
28. Kochiadakis G.E., et al. Vascular endothelial growth factor protein levels and gene expression in peripheral monocytes after stenting: a randomized comparative study of sirolimus: eluting and bare metal stents. Eur. Heart J. 29 (2008) 733-740
29. Lambooij A.C., van Wely K.H., Lindenbergh-Kortleve D.J., Kuijpers R.W., Kliffen M., and Mooy C.M. Insulin-like growth factor-I and its receptor in neovascular age-related macular degeneration. Invest. Ophthalmol. Vis. Sci. 44 (2003) 2192-2198
30. Hera R., Keramidas M., Peoc'h M., Mouillon M., Romanet J.P., and Feige J.J. Expression of VEGF and angiopoietins in subfoveal membranes from patients with age-related macular degeneration. Am. J. Ophthalmol. 139 (2005) 589-596
31. Shi X., Semkova I., Muther P.S., Dell S., Kociok N., and Joussen A.M. Inhibition of TNF-alpha reduces laser-induced choroidal neovascularization. Exp. Eye Res. 83 (2006) 1325-1334
32. 2+ channels in retinal pigment epithelial cells regulate vascular endothelial growth factor secretion rates in health and disease. Mol. Vis. 13 (2007) 443-456
33. Tatar O., et al. Matrix metalloproteinases in human choroidal neovascular membranes excised following verteporfin photodynamic therapy. Br. J. Ophthalmol. 91 (2007) 1183-1189
34. Rosenthal R., and Strauss O. Investigations of RPE cells of choriodal neovascular membranes from patients with age-related macula degeneration. Adv. Exp. Med. Biol. 533 (2003) 107-113
35. Martin G., Schlunck G., Hansen L.L., and Agostini H.T. Differential expression of angioregulatory factors in normal and CNV-derived human retinal pigment epithelium. Graefes. Arch. Clin. Exp. Ophthalmol. 242 (2004) 321-326
36. Stavri G.T., Zachary I.C., Baskerville P.A., Martin J.F., and Erusalimsky J.D. Basic fibroblast growth factor upregulates the expression of vascular endothelial growth factor in vascular smooth muscle cells. Synergistic interaction with hypoxia. Circulation 92 (1995) 11-14
37. Seghezzi G., et al. Fibroblast growth factor-2 (FGF-2) induces vascular endothelial growth factor (VEGF) expression in the endothelial cells of forming capillaries: an autocrine mechanism contributing to angiogenesis. J. Cell Biol. 141 (1998) 1659-1673
38. Zubilewicz A., Hecquet C., Jeanny J.C., Soubrane G., Courtois Y., and Mascarelli F. Two distinct signalling pathways are involved in FGF2-stimulated proliferation of choriocapillary endothelial cells: a comparative study with VEGF. Oncogene 20 (2001) 1403-1413
39. Im E., and Kazlauskas A. Regulating angiogenesis at the level of PtdIns-4,5-P2. EMBO J. 25 (2006) 2075-2082
40. Sun S.Y., Rosenberg L.M., Wang X., Zhou Z., Yue P., Fu H., and Khuri F.R. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res. 65 (2005) 7052-7058
41. Fan Q.W., Knight Z.A., Goldenberg D.D., Yu W., Mostov K.E., Stokoe D., Shokat K.M., and Weiss W.A. A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell 9 (2006) 341-349
42. Bjornsti M.A., and Houghton P.J. The TOR pathway: a target for cancer therapy. Nat. Rev. Cancer 4 (2004) 335-348